| Analysts were expecting Mylan, Inc. (MYL) [Chart - News - Analysis] to report earnings of $0.27 for last quarter, but MYL beat expectations with actual earnings of $0.32---5 cents above the consensus estimate. MYL also issued earnings guidance for next quarter that is above current analyst expectations. If you compare last quarter's earnings to the $0.23 the company made per share during the same quarter a year ago, you can see that MYL’s earnings are up this year. Check this out (it's free!): Stocks You Should Be Watching Right Now; How to Make Good Picks
| | | | | |
-
Essential Reading for Traders
-
| | |
| | | | | | | | Also, if you compare MYL's 18.66% projected earnings-per-share (EPS) growth rate for the next five years with the projected EPS growth rate of 16.65% for the Drugs - Generic industry as a whole during that same time frame, you can see that analysts expect MYL to outperform the industry in the future---which is a good sign for the stock. Drilling down a little deeper into the Drugs - Generic industry, you can see how analysts believe MYL will stack up against some of the other stocks in the industry, like Watson Pharmaceuticals Inc. (WPI) [Chart - News - Analysis] and Par Pharmaceutical Companies Inc. (PRX) [Chart - News - Analysis], in the future. Analysts believe WPI's earnings are going to grow at a rate of 15.64% while PRX's earnings are going to grow at a rate of 7.00%. Earnings season can be a volatile time in the stock market. Check out these videos and articles to be better prepared to take advantage of the large price moves that tend to accompany earnings announcements. - Earnings Season is Here - Find Out How to Trade It - Using Options to Trade Earnings - Understanding Stock Analyst Research and Recommendations More...
Keep up with us:
| 
